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ABSTRACT   
Background. Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a difficult-to-
diagnose cause of sudden cardiac death (SCD). We identified a family of 1400 individuals with 
multiple cases of CPVT, including 36 SCDs during youth. 
Objectives. We sought to identify the genetic cause of CPVT in this family, to preventively treat and 
clinically characterize the mutation-positive individuals, and to functionally characterize the 
pathogenic mechanisms of the mutation.  
Methods. Genetic testing was performed for 1,404 relatives. Mutation-positive subjects were 
preventively treated with beta-blockers and clinically characterized with a serial exercise treadmill test 
(ETT) and Holter monitoring. In vitro functional studies included caffeine sensitivity and store 
overload-induced calcium release activity (SOICR) of the mutant channel in HEK 293 cells.  
Results. We identified the p.G357S_RyR2 mutation, in the cardiac ryanodine receptor, in 179 family 
members and in 6 SCD victims. No SCD was observed among treated mutation-positive subjects over 
a median 37-month follow-up; however, three relatives who had refused genetic testing (confirmed 
mutation-positive subjects) experienced SCD. Holter monitoring did not provide relevant information 
for CPVT diagnosis. One single ETT was unable to detect complex cardiac arrhythmias in 72% of 
mutation-positive subjects, though serial ETT improved the accuracy. Functional studies showed that 





Conclusion. Our study supports the use of genetic testing to identify individuals at risk of SCD to 
undertake prophylactic interventions. We also show that the pathogenic mechanisms of 
p.G357S_RyR2 appear to depend on beta-adrenergic stimulation.  
 
Key words: Arrhythmias, genetic testing, CPVT, RyR2, SOICR, sudden cardiac death.  
 
Glossary of abbreviations: 
CPVT: Catecholaminergic polymorphic ventricular tachycardia 
CVA: Complex ventricular arrhythmias  
ETT: Exercise treadmill test  
ICD: Implantable cardioverter defibrillator  
PKA: cAMP-dependent protein kinase 
PVC: Premature ventricular contractions   
SCD: Sudden cardiac death 
SOICR: Store overload-induced calcium release  
TMHR: Theoretical maximum heart rate  
VA: Ventricular arrhythmia  
 
INTRODUCTION 
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is one of the most difficult sudden 
cardiac death (SCD)-associated diseases to manage
1,2
; indeed, CPVT risk stratification remains 
unclear.
3
 Initially described by Coumel et al.,
4
 CPVT is an inherited disease characterized by the 




with a normal basal electrocardiogram and structurally normal heart. CPVT patients can present 
syncope and SCD triggered by physical or emotional stress at young ages, and SCD can be the first 
manifestation in up to 30% of cases.
5–7
 Symptom onset can be very early (between 7-9 years of 
age).
1,5,8
 As these patients display normal ECG and no structural cardiac abnormalities, there is usually 
a delay in the diagnosis of the disease.
5
 The main tools used in the diagnosis of CPVT are exercise 
treadmill test (ETT) and ECG Holter monitoring.
9,10
  
Genetic links to CPVT were established in 1999 for the type 2 ryanodine receptor (RyR2)
11
 and in 
2001 for calsequestrin (CASQ2).
12
 However, heterogeneity in phenotypic expression of these genetic 
mutations was soon demonstrated, with an average disease penetrance of 54%
3,13
.  The variable 
phenotype resulting from a single mutation among members of an affected family, suggests that 
additional factors might play a role in the phenotypic expression of RyR2 mutations, which highlights 
the need for a mechanistic understanding of the disease. 
Only 22 of the 176 mutations in RyR2 that have been associated with CPVT have been functionally 
characterized in cellular models.
14





 SOICR is proposed to elicit Ca-activated inward currents 
through the activation of the sodium calcium exchanger in the plasma membrane. This can alter the 
surface membrane potential and generate early and delayed afterdepolarizations, which in turn can 
lead to triggered arrhythmia (for review see Priori & Chen).
20
   
We present here a family affected by SCD with more than 1400 living members. These individuals 
share a common ancestor born in 1749. Within this family, SCD has occurred at young ages during 
exercise and stress but in individuals with a normal basal electrocardiogram, therefore we suspected 
CPVT. To determine the genetic cause of SCD in this cohort, we performed genetic analysis. After 
identifying a potentially causal mutation in the RyR2 gene in one individual with SCD, we performed 
in vitro functional studies to determine the underlying mechanism in the mutant channel. Additionally, 
we used genetic screening of 1,404 living family members to identify individuals in the family at risk 




findings of this study underscore the utility of genetic screening for ascertaining individuals at risk of 
SCD.  
METHODS  
Detailed methods are provided in the Supplementary Material.  
RESULTS 
Family history  
Between 1994 and 2007, four apparently non-related families from Gran Canaria Island (Spain) were 
investigated due to several episodes of SCD in young individuals (Figure 1A). In one of these families 
(Family 1, Figure 1A) CPVT was suspected because three of the four daughters had experienced SCD 
during emotional or physical stress. After ascertaining the four separate families, we suspected a high 
degree of kinship because all individuals were inhabitants of Gran Canaria Island, a relatively isolated 
population. Indeed, a genealogic study between these families allowed us to identify a single, large 
family with more than 1,400 living family members and a common ancestor who was born in 1749 
(Figure 1B). There were 30 more SCD cases in the family whose deaths were suggestive of CPVT. 
Genetic Analysis 
Because mutations in RyR2 and CASQ have been correlated with CPVT, the coding regions of these 
two genes were selected for an initial genetic analysis. Genetic analysis of the index case, a deceased 
member of family 1, (Figure 1A) revealed a missense mutation in exon 13 of the RyR2 gene, in which 
adenine was substituted for guanine at base position 1069 of the coding sequence (Chr1: 237604682 
G>A -Hg19-); this resulted in a glycine to serine substitution at residue 357
 
of the RyR2 protein 
(p.G357S_RyR2, NP_001026.2) (Figure 2). To identify possible additional mutations in ion channels, 
we also analyzed 55 genes previously associated with SCD using next-generation sequencing in the 
index case; only the p.G357S_RyR2 mutation was detected. The mutation was absent in 580 control 
alleles from the healthy population and was not found in the general population according to the locus-




showed that the p.G357S_RyR2 variation was predicted to be „„probably damaging‟‟ by PolyPhen-2, 
“deleterious” by Condel, Provean, and PhDSNP, and “pathological” by Pmut. A previous report about 
the p.G357S_RyR2 mutation showed that G357 residue in RyR2 was conserved among species, but its 
pathogenicity was unclear because no data about the co-segregation had been previously described.
21
  
Familial genetic analysis in patients with documented ventricular arrhythmias (VA) and in six SCD 
victims with available DNA revealed that all of them had the p.G357S_RyR2 mutation. A cascade 
screening performed in 1,404 family members identified 179 living p.G357S_RyR2 mutation-positive 
subjects.  
 
Functional characterization of the G357S mutation in basal conditions  
To functionally characterize the effect of the G357S mutation, stable and inducible HEK293 cell lines 
expressing RyR2 WT or G357S were generated. Both cell lines showed RyR2 expression after 48 h of 
tetracycline induction, and no RyR2 expression was observed in the absence of tetracycline 
(Supplementary Figure 1). Calcium imaging experiments were used to evaluate the activity of the 
RyR2 channels in terms of caffeine sensitivity and SOICR activity as a function of extracellular Ca
2+
. 
The evaluation of RyR2 caffeine sensitivity showed no significant differences between the RyR2 WT 
and RyR2 G357S variant (EC50WT = 0.16 ± 0.08 mM vs EC50G357S = 0.21 ± 0.04 mM) (Figure 3A and 
B). Additionally, the SOICR analysis showed no shift between the SOICR curves and no significant 
differences in the EC50 for extracellular Ca
2+
 (EC50WT = 0.74 ± 0.03 mM vs. EC50G357S = 0.71 ± 0.03 
mM) (Figure 3C and D). 
 
Functional characterization of the G357S mutation in conditions that mimic catecholaminergic 
stress 
Increased sympathetic activity is a typical physiologic response to stress, and is thought to be the basis 
of arrhythmias in CPVT. Activation of the adrenergic signaling pathway generates increased cAMP 
levels and activates protein kinase A (PKA). In the heart, activated PKA can phosphorylate RYR2 at 




probability of RyR2 promoting a Ca
2+
 leak from the sarcoplasmic reticulum.
22,23
 To evaluate the 
activity of the RyR2 channel in conditions that mimic catecholaminergic stress, calcium-imaging 
experiments were performed using forskolin to increase intracellular levels of cAMP. Caffeine 
sensitivity of the G357S channel was higher than that of the WT channel in the presence of forskolin 
(Figure 4A and B). We observed a significant shift to the left for the G357S caffeine curve, which 
produced significant differences between the EC50 under conditions that mimic catecholaminergic 
stress (EC50WT = 0.095 ± 0.01 mM and EC50G357S = 0.069 ± 0.01 mM, p < 0.0001, n = 7; Figure 4B). 
Further, in the presence of forskolin, SOICR activity was significantly higher in cells expressing RyR2 
G357S than in cells expressing RyR2 WT, e.g., at 500 µM Ca
2+
 the oscillation per minute was 1.21 ± 
0.04 for WT cells and 1.55 ± 0.05 for G357S cells (p < 0.0001 nWT = 234, nG357S = 298, Figure 4C and 
D). Additionally, forskolin modulated spontaneous release activity in a concentration-dependent 
fashion (Figure 4E), and RyR2 G357S cells had a greater response to increasing concentrations of 
forskolin. At 5 μM forskolin, the number of oscillations was 1.25 ± 0.02 for WT cells and 1.43 ± 0.02 
for G357S cells (p < 0.001, n=6).  
 
Analysis of RyR2 phosphorylation 
Due to the differential response of cells harboring WT or mutant RyR2 channels to elevated cAMP 
levels, we hypothesized that the introduction of S357 may create a new PKA phosphorylation site, 
which could be phosphorylated in the presence of forskolin. We first immunopurified G357S RyR2 
from forskolin-treated cells, and subjected it to proteomic analysis. Although protein coverage was 
relatively high (~40%) for such a large membrane protein (Supplementary Figure 2), the peptide 
containing S357 (tryptic peptide spanning residues Y355 to K380) was not detected by our mass 
spectrometric analysis. In an attempt to increase sequence coverage, we digested the same sample with 
chymotrypsin, but no peptide containing S357 was observed after mass spectrometric analysis. 
We then decided to perform PKA phosphorylation assays in vitro, using synthetic peptides containing 






Baseline characteristics of SCD members and living mutation-positive subjects   
Thirty-six SCDs had occurred in the family, and at a young age (< 42 years old, Table 1); most were in 
the last 20 years. Of all SCD events, 69.4% occurred in males, and 77.4% of deaths were associated 
with exercise or emotional stress. In the SCD group, the presence of previous symptoms, especially 
syncope (73% of cases), was common. In 22% of SCD victims with reliable data, SCD was the first 
manifestation of the disease. In the group of living mutation-positive individuals, 25.9% had presented 
symptoms before p.G357S_RyR2 was detected (Table 1 and Supplementary Table 3). The basal mean 
heart rate, without treatment, measured by 24-hour Holter was significantly lower (p= 0.011) in 
mutation-positive subjects (71.0 ± 10.6 bpm, n= 139) than in control subjects (76.3 ± 10.2 bpm, n=32). 
Sinus bradycardia, measured by basal ECG, occurred in 18.2% of mutation-positive individuals and in 
3.1% of controls (p=0.009), adjusted by age in children under 16.
24
 Given the malignancy of CPVT 
and the high frequency of SCD in the family, we decided to preventively treat all mutation-positive 
individuals with beta-blockers. One patient was additionally treated with flecainide because of 
paroxysmal atrial fibrillation and another was treated with calcium channel blockers due to high blood 
pressure. No sympathectomy was performed. 
 
Clinical investigation in mutation-positive subjects  
Basal ETTs were performed in 150 mutation-positive subjects under no pharmacological treatment as 
soon as genetic diagnosis was confirmed. Disease penetrance and expression in these individuals were 
heterogeneous. During basal ETT, 28% of mutation-positive individuals exhibited complex VA 
(CVA) (1.4% in controls); the proportion grew to 46.3% (10% in controls) if VA was considered. The 
accuracy of basal ETT to diagnose mutation-positive subjects was 0.504 for CVA and 0.586 for VA 
(Table 2). Mutation-positive individuals treated with beta-blockers (n = 138) were clinically 
investigated with serial ETT (Table 3). With a mean/median of 6.5/7 ETT per patient, 1121 ETT were 
performed: 149 without treatment, 549 on Bisoprolol [mean maximum dose (MMD) = 7.5 ± 5 mg], 




blockers. Bisoprolol was preferentially used because it is taken once daily and, although it seems that 
Nanodol provides superiority of protection in CPVT,
2
 it was not used in our protocol because it is 
scarcely available in Spain.  We analyzed the two most used beta-blockers in our study in a series of 
43 patients who took both treatments at different times. This series shows that the mean quantitative 
arrhythmia score (AS), considering ventricular ectopic beats (AS-1), was 64.73 for Bisoprolol and 
29.43 for Propranolol (p<0.001) and, considering CVA (AS-2), was 52.40 and 12.28, respectively 
(p<0.001). 
 Serial ETT proved to be effective in uncovering at least one VA-positive test in mutation-positive 
subjects, despite beta-blockers. After 10 ETT, 74% of p.G357S_RyR2-positive subjects showed CVA, 
and if VA was considered, this proportion reached 91% (Table 3). A total of 750 Holter monitorings 
were performed during the follow-up (mean 4.3 Holter/ mutation-positive subjects); its accuracy 
(0.360) to diagnose CPVT in mutation-positive individuals was inferior to the ETT accuracy (Table 2).  
Clinical events at follow-up 
Implantable cardioverter defibrillators (ICD) were implanted in 22% of mutation-positive subjects (n = 
40); 6 of them were implanted before the beginning of the protocol. The reasons for implantation were 
presyncope (n = 4, 10%), syncope (n = 20, 50%), and complex VA (CVA; n = 16, 40%) despite beta-
blocker treatment. After more than five years of ICD implantation, five ICD events have been 
recorded in four patients: two non-sustained ventricular tachycardia (VT) (287 & 250 bpm) and three 
ICD discharges (VT-FV, 303 ± 21 bpm). Patients who received discharges were off beta-blockers for 
personal reasons. We only recorded 1 inappropriate discharge (inappropriate shock rate: 0.32 per 
year). The cumulative incidence of symptoms (dizziness or syncope) in mutation-positive subjects 
under protocol was 11%, and no SCD has been reported in this group since our intervention (Figure 
5). Another 53 family members were potential mutation-positive individuals but refused genetic 
testing and clinical evaluation. These individuals were asymptomatic but considered at risk because 
they were either first-degree relatives of SCD victims or of G357S-positive subjects. During the 




16-year-old boy who died suddenly while playing at a music hall, a 31-year-old man who died while 
exercising, and a 38-year-old woman who experienced an aborted SCD. All of them were 
subsequently identified as p.G357S_RyR2-positive subjects . 
 
DISCUSSION  
We report the association of the p.G357S_RyR2 variation with CPVT. Our experimental evidence 
supports the pathogenic role of this founder mutation and a plausible mechanism that helps explain the 
phenotype. We actively performed cascade screening, involving genealogical studies, to identify 
individuals at risk. We present the clinical work-up of 179 mutation-positive subjects, all members of 
a large family from the Canary Islands. This identical mutation series constitutes the largest CPVT 
series studied so far. The reliability for the screening of CPVT using the currently recommended 
clinical diagnostic approach is controversial, and seems to have very low sensitivity, especially with a 
single test. 
Functional characterization of G357S RyR2 channel 
The majority of functional studies of RyR2 mutations associated with CPVT performed to date show 
an enhanced propensity for SOICR activity in cells expressing mutant channels
15–19
 and higher 
sensitivity to caffeine.
25
 This is not the case for p.G357S_RyR2, which, in basal conditions, does not 
produce an increase in the SOICR activity nor an increase in the sensitivity to caffeine of the channel. 
However, SOICR of G357S cells and their sensitivity to caffeine was much greater in conditions that 
mimic beta-adrenergic stimulations. Loaiza et al.
26
 showed that the SOICR activity of RyR2 was not 
modified by the V2475F RyR2 mutation; however, beta-adrenergic stimulated ventricular myocytes 
from V2475F +/- mice showed an increased propensity for spontaneous Ca
2+
 release events, which is 
very reminiscent of our observations. In the present study, in vitro experiments indicate that the 
mutated site, S357, itself is unlikely to be a target for PKA phosphorylation. Moreover, the recently 
published structure of RyR1
27
 strongly suggests that large molecules like kinases would be sterically 




pathogenicity might depend on beta-adrenergic stimulation, which may underlie the variable 
phenotypic expression and incomplete penetrance of the disease in this family. Nevertheless, the 
description of the precise mechanism(s) that underlie pathogenicity of RyR2 G357S exceeds the scope 
of the present manuscript. 
Clinical evaluation 
Although ETT and Holter monitoring are currently recommended methods for CPVT diagnosis
9
, our 
clinical investigation, based on these methods, would not have diagnosed a significant proportion of 
mutation-positive subjects in this family. Holter monitoring for 24 hours did not provide relevant 
information for the diagnosis of CPVT. Notably, the performance of only one ETT misdiagnosed 54% 
of mutation-positive individuals (72% if CVA is used as threshold). Our serial ETT protocol notably 
improved sensitivity, and we strongly recommend the performance of several ETTs if CPVT is 
suspected in individuals with unavailable genetic testing. The protocol we used, based on 3 months of 
serial ETT and beta-blocker titration to achieve ≤ 80 % theoretical maximum heart rate (TMHR) and 
no VA, was very effective. Our results also suggest that Propranolol was more effective than 
Bisoprolol to prevent quantity and severity of ventricular arrhythmias in the stress test.  No fatal 
events occurred in patients under our protocol. However three SCDs (one aborted) occurred in the 
group of family members that refused genetic testing and were not treated. These results reinforce the 
current clinical guidelines, which suggest that mutation-positive family members could receive beta-




The present study provides important mechanistic insight to establish likely disease-causative links for 
this mutation. Our findings suggest that cAMP elevation unmasks a concealed pathogenic behavior of 
the G357S RyR2 channel. Our study also supports recent claims that advocate for the use of genetic 
testing to identify individuals at risk of SCD to undertake prophylactic interventions.
28
 We 




management of CPVT and should be recommended to all CPVT mutation-positive subjects in the 
absence of reliable risk stratification tools. 
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Our study provides evidence that genetic testing can become the first screening tool for primary 
prevention of SCD in large families, especially in those diseases in which there are effective, 
noninvasive therapies available. We demonstrate the efficacy of a protocol based on beta-blockers and 
serial ETT in management of CPVT. We recommend this close follow-up (every 3 months) to all 
CPVT mutation-positive individuals. Additional research is needed to determine whether 
p.G357S_RyR2-positive subjects experience a varied degree of arrhythmogenic events depending on 
the level of sympathetic activation. This may provide a rationale for the incomplete penetrance of the 
disease in this family. 
 
FIGURE LEGENDS 
Figure 1. Family pedigrees. A. Pedigrees of the 4 related families from Gran Canaria. Circles 
represent female and squares represent male subjects. Points indicate mutation-positive subjects. 
Painted symbols indicate family members diagnosed with CPVT. Labeled symbols represent family 
members who experienced SCD. Interrogation mark indicates unknown genotype. The index case is 
indicated by an arrow. B. Pedigree of the large family from the Canary Islands with a common 
ancestor and more than 1,400 living family members. It includes the four families from Figure 1A. 
Figure 2. Electropherogram of the G357S RyR2 mutation. Sequencing analysis of genomic DNA 
revealed a missense mutation at position 1069 of the coding sequence of the RyR2 gene, corresponding 
to exon 13 (Chr1: 237604682 G>A -Hg19-). This nucleotide change results in a glycine to serine 
substitution in the 357th residue of the protein sequence (p.G357S_RyR2, NP_001026.2). 
Figure 3. Functional characterization of the RyR2 WT and mutant channel under basal 
conditions. A. Representative fluorescence over time traces, from multiple cells, showing caffeine-
induced transients. B. Normalized amplitudes of Ca
2+
 transients are plotted as a function of caffeine 
concentration. No differences were found in sensitivity to caffeine between WT and G357S RyR2 
expressing cells. C. Representative fluorescence over time traces, from 30 cells, showing SOICR 
activity of WT and G357S cells in 0.3 mM Ca
2+
 and in 1 mM Ca
2+
, each color represents one cell. D. 
Oscillations per oscillating cells as a function of increasing extracellular Ca
2+
. No differences were 
found in SOICR activity between cells expressing RyR2 WT and the G357S variant. 
Figure 4. Functional characterization of the RyR2 WT and mutant channel in conditions that 




cells, showing caffeine-induced transients in the presence of forskolin. B. Normalized amplitudes of 
Ca
2+
 transients are plotted as a function of caffeine concentration with forskolin. The G357S RyR2-
expressing cells show higher caffeine sensitivity in the presence of forskolin than do WT RyR2-
expressing cells. C. Representative traces of SOICR activity of cells expressing RyR2 WT or G357S 
in 200 µM Ca
2+
. Each trace represents individual cell fluorescence (54 cells imaged). Left panels show 
the frequency of oscillations in 200 µM Ca
2+ 
for both cell types. Right panels show the increase in 
frequency and in number of oscillations with the forskolin treatment, with a greater change in activity 
in RyR2 G357S cells. D. Oscillations per minute as a function of Ca
2+
, with or without 5 µM 
forskolin. SOICR activity is higher in cells expressing RyR2 G357S protein in the presence of 
forskolin. E. Number of oscillations per oscillating cells as a function of forskolin concentration. The 
G357S mutant channel-expressing cells show a higher SOICR activity in the presence of forskolin 
than WT RyR2 cells.  
Figure 5. Prevalence of SCD during the follow-up. Incidence of SCD or cardiac arrest between 
1994 and 2013, before and after the identification of the p.G357S variation in RyR2 in this large 
family from Gran Canaria.  
 







Age of death (mean ± SD) 18.1 ± 8.8 * - - 
Age at genetic diagnosis (mean ± SD) - 38.5 ± 20.8  
Male gender (%) 69.4 44.1 0.006
a
 
Symptoms (%)† 75 25.9 < 0.001
b
 
Dizziness (%) 14.3 10.0 0.642
a
 
Syncope (%) 73.7 17.9 < 0.001
a
 
Syncope, age of onset (mean ± SD) 14.1 ± 6.5 24.7±17.5 0.286
 c
 






Table 2.  Evaluation of basal exercise treadmill test (ETT) and Holter monitoring 
Basal Test  VA-ETT (n = 220) CVA-ETT (n = 220) VA-Holter (n = 166) 
Sensitivity (%)  46.0 28.0 21.6 
Specificity (%)  85.7 98.6 84.4 
PPV* (%)  87.3 97.7 85.3 
NPV *(%)  42.5 39.0 20.5 
Accuracy 0.586 0.504 0.360 
*PPV: positive predictive value; NPV: negative predictive value 
 










N n % 
 
n % 
Arrhythmias ETT1 150 69 46.0 
 
42 28.0 
Arrhythmias ETT1-pe2 141 78 55.3 
 
53 37.5 
Arrhythmias ETT1-pe3 132 91 67.9 
 
59 44.6 
Arrhythmias ETT1-pe4 131 96 72.7 
 
63 48.1 
Arrhythmias ETT1-pe5 130 99 76.2 
 
68 52.3 
Arrhythmias ETT1-pe6 127 101 79.5 
 
70 55.1 
Arrhythmias ETT1-pe7 120 101 84.2 
 
73 60.8 
Arrhythmias ETT1-pe8 116 102 87.9 
 
79 68.1 
Arrhythmias ETT1-pe9 114 103 90.4 
 
82 71.9 
Arrhythmias ETT1-pe10 114 104 91.2 
 
85 74.5 
N: patients available for analysis.  n= Mutation-positive subjects with arrhythmias in the ETT 
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